Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$102.58 USD

102.58
1,931,139

+1.92 (1.91%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $102.37 -0.21 (-0.20%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (202 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio

by Zacks Equity Research

Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.

ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40

by Zacks Equity Research

ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.

Here's Why You Should Hold on to Neogen (NEOG) Stock Now

by Zacks Equity Research

Solid progress in long-term growth strategies bodes well for Neogen (NEOG).

Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JPUS

Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable

by Zacks Equity Research

Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag

by Zacks Equity Research

Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.

DaVita (DVA) Expands Operational Footprint Via New Agreement

by Zacks Equity Research

DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.

Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth

by Zacks Equity Research

With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.

Are Investors Undervaluing Cardinal Health (CAH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Stryker (SYK) Completes First Arthroplasty Surgery in Europe

by Zacks Equity Research

Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.

DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval

by Zacks Equity Research

DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.

The Zacks Analyst Blog Highlights The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works

by Zacks Equity Research

The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works are included in this Analyst Blog.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High With More Upside Potential

by Vasundhara Sawalka

Investors target stocks that have lately been on a bull run. Stocks like PPC, SUN, CAH and TXT are seeing price strength and have a high chance of carrying the momentum forward.

Haemonetics (HAE) Signs Agreement to Acquire Attune Medical

by Zacks Equity Research

Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.

Best Growth Stocks to Buy for March 6th

by Zacks Equity Research

PAGS, CAH and NVDA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 6, 2023.

Derek Lewis headshot

3 Top-Ranked Stocks to Buy for Stability

by Derek Lewis

Targeting low-beta stocks can provide a valuable layer of stability for portfolios. After all, defense wins ballgames.

Reasons to Retain Prestige Consumer (PBH) Stock for Now

by Zacks Equity Research

Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.

CVS Health (CVS) Expands In-Home Diagnostic Care With New Test

by Zacks Equity Research

CVS Health's (CVS) new launch will enable early detection of heart arrhythmia and can help mitigate symptoms and more severe complications.

Here's Why You Should Add Ecolab (ECL) to Your Portfolio

by Zacks Equity Research

Ecolab's (ECL) focus on R&D raises optimism about the stock.

Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use

by Zacks Equity Research

Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.